Best Hospitals for Ovarian Cancer Treatment in Hyderabad, India

The total cost of ovarian cancer treatment — covering primary cytoreductive surgery, 6–8 days of hospitalisation, standard medications, and 6 cycles of adjuvant carboplatin/paclitaxel chemotherapy — ranges from approximately $8,000 to $22,000 USD in India, depending on the stage of disease, extent of surgery (standard debulking vs. HIPEC), and the specific institution. In the UAE (Dubai or Abu Dhabi), equivalent treatment ranges from $18,000 to $45,000 USD, reflecting the higher infrastructure and operational costs of GCC healthcare. HIPEC (Hyperthermic Intraperitoneal Chemotherapy), when indicated, adds roughly $4,000–$6,000 in India and $10,000–$15,000 in the UAE. PARP inhibitor maintenance therapy (olaparib, niraparib) — prescribed for BRCA-mutated or HRD-positive patients after completing chemotherapy — costs an additional $1,500–$3,000 per month and is not typically included in surgical package pricing. India therefore offers savings of 40–65% compared to the UAE, while both destinations offer JCI-accredited centres, robotic surgery platforms, and molecular diagnostic services. GAF Healthcare provides a personalised, itemised cost estimate based on the patient's specific staging workup before any commitment is made.

The minimum safe in-country stay before international flight clearance depends primarily on the treatment modality. For patients undergoing open primary cytoreductive surgery (the most common approach for advanced-stage disease), the fit-to-fly milestone is typically 5–6 weeks post-surgery. This accounts for full wound healing, return of bowel function, haemodynamic stability, resolution of any post-operative complications (pleural effusion, anaemia), and the administration of the first cycle of adjuvant chemotherapy — which oncologists prefer to complete locally to monitor for initial toxicity. Patients who undergo robotic-assisted minimally invasive surgery (typically for early-stage or interval debulking) can generally achieve fit-to-fly status in 3–4 weeks. Patients receiving chemotherapy only (without surgery, e.g. neoadjuvant NACT prior to interval surgery, or palliative-intent treatment) may fly home between cycles — approximately 72–96 hours after infusion — with written clearance from their oncologist, as long as blood counts are adequate. HIPEC patients require an extended stay of 6–8 weeks due to the additional haematological and renal monitoring required. All patients flying after major abdominal surgery are provided with a written fit-to-fly letter, deep vein thrombosis prophylaxis (compression stockings and low-molecular-weight heparin for 10–14 days), and a comprehensive clinical handover package for their home-country oncologist. GAF Healthcare confirms fit-to-fly clearance formally before booking the patient's return flight.

Success rates for ovarian cancer are measured by 5-year overall survival and are directly determined by FIGO stage at diagnosis and the quality of initial surgical cytoreduction — specifically whether R0 resection (no macroscopic residual tumour) is achieved. At GAF Healthcare's partner institutions — including Tata Memorial Hospital (Mumbai), Apollo Cancer Centres, Manipal Hospitals (India) and Cleveland Clinic Abu Dhabi, Mediclinic City Hospital, and American Hospital Dubai (UAE) — published and institutional outcomes are as follows: Stage I: 85–93% 5-year survival; Stage II: 70–80%; Stage III with R0 resection: 40–50%; Stage III with residual disease >1 cm: 20–30%; Stage IV: 20–30% with optimal cytoreduction and bevacizumab/PARP inhibitor maintenance. The incorporation of PARP inhibitor maintenance (olaparib) in BRCA-mutated patients has dramatically improved progression-free survival — the SOLO-1 trial demonstrated that at 5 years, 48% of BRCA-mutated patients on olaparib maintenance had not experienced disease progression versus only 21% on placebo. Chemotherapy response rates to first-line carboplatin/paclitaxel reach 70–80% (objective response), though platinum resistance develops in the majority of advanced-stage patients within 2 years. It is important to understand that success in ovarian cancer management is increasingly defined not by cure alone, but by sustained quality of life, prolonged progression-free survival, and the ability to sequence effective therapies at recurrence — an approach that requires the level of multidisciplinary expertise and molecular diagnostics available at GAF Healthcare's partner centres.